| Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors—a single‐center cohort AA Barg, E Avishai, I Budnik, S Levy‐Mendelovich, TB Barazani, G Kenet, ... Pediatric Blood & Cancer 66 (11), e27886, 2019 | 87 | 2019 |
| Emicizumab treatment and monitoring in a paediatric cohort: real‐world data AA Barg, T Livnat, I Budnik, E Avishai, T Brutman‐Barazani, I Tamarin, ... British Journal of Haematology 191 (2), 282-290, 2020 | 72 | 2020 |
| Emicizumab prophylaxis: prospective longitudinal real‐world follow‐up and monitoring AA Barg, I Budnik, E Avishai, T Brutman‐Barazani, D Bashari, M Misgav, ... Haemophilia 27 (3), 383-391, 2021 | 53 | 2021 |
| Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: real‐world data M Misgav, T Brutman‐Barazani, I Budnik, E Avishai, J Schapiro, D Bashari, ... Haemophilia 27 (2), 253-260, 2021 | 34 | 2021 |
| Real-world data on bleeding patterns of hemophilia A patients treated with emicizumab S Levy-Mendelovich, T Brutman-Barazani, I Budnik, E Avishai, AA Barg, ... Journal of Clinical Medicine 10 (19), 4303, 2021 | 28 | 2021 |
| The potential role of emicizumab prophylaxis in severe von Willebrand disease AA Barg, E Avishai, I Budnik, TB Brutman, I Tamarin, R Dardik, D Bashari, ... Blood Cells, Molecules, and Diseases 87, 102530, 2021 | 24 | 2021 |
| Molecular mechanisms of skewed X-chromosome inactivation in female hemophilia patients—lessons from wide genome analyses R Dardik, E Avishai, S Lalezari, AA Barg, S Levy-Mendelovich, I Budnik, ... International Journal of Molecular Sciences 22 (16), 9074, 2021 | 21 | 2021 |
| Single low dose of rFVIIa combined with antifibrinolytic agent is a simple and safe treatment for factor XI-deficient patients undergoing surgery O Salomon, I Budnik, E Avishai, I Tamarin, D Bashari, R Dardik, T Livnat Thrombosis and Haemostasis 119 (12), 1927-1932, 2019 | 11 | 2019 |
| Combination of hemostatic therapies for treatment of patients with hemophilia A and inhibitors T Livnat, I Budnik, S Levy-Mendelovich, E Avishai, M Misgav, AA Barg, ... Blood Cells, Molecules, and Diseases 66, 1-5, 2017 | 11 | 2017 |
| Four decades of carrier detection and prenatal diagnosis in hemophilia A: historical overview, state of the art and future directions R Dardik, S Janczar, S Lalezari, E Avishai, S Levy-Mendelovich, AA Barg, ... International Journal of Molecular Sciences 24 (14), 11846, 2023 | 9 | 2023 |
| A novel approach using ancillary tests to guide treatment of Glanzmann thrombasthenia patients undergoing surgical procedures AA Barg, H Hauschner, M Misgav, A Lubetsky, S Levy-Mendelowitz, ... Blood Cells, Molecules, and Diseases 72, 44-48, 2018 | 8 | 2018 |
| Women with hemophilia: Case series of reproductive choices and review of literature S Lalezari, AA Barg, R Dardik, J Luboshitz, D Bashari, E Avishai, G Kenet TH Open 5 (02), e183-e187, 2021 | 7 | 2021 |
| Pediatric severe factor XI deficiency: A multicenter study AA Barg, S Levy‐Mendelovich, I Budnik, N Mandel‐Shorer, R Dardik, ... Pediatric Blood & Cancer 69 (3), e29545, 2022 | 6 | 2022 |
| Treatment tailoring for factor V deficient patients and perioperative management using global hemostatic coagulation assays S Levy-Mendelovich, AA Barg, N Rosenberg, E Avishai, J Luboshitz, ... Blood Cells, Molecules, and Diseases 71, 5-10, 2018 | 6 | 2018 |
| Alternative treatment options for pediatric hemophilia B patients with high‐responding inhibitors: A thrombin generation‐guided study AA Barg, S Levy‐Mendelovich, E Avishai, R Dardik, M Misgav, G Kenet, ... Pediatric Blood & Cancer 65 (12), e27381, 2018 | 5 | 2018 |
| Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes S Levy-Mendelovich, N Atia, I Budnik, AA Barg, E Avishai, O Cohen, ... Research and Practice in Thrombosis and Haemostasis 7 (4), 100278, 2023 | 4 | 2023 |
| Association between thrombin generation and clinical characteristics in COVID-19 patients O Cohen, N Landau, E Avisahai, T Brutman-Barazani, I Budnik, T Livnat, ... Acta Haematologica 146 (2), 151-160, 2023 | 4 | 2023 |
| Anti-TFPI for hemostasis induction in patients with rare bleeding disorders, an ex vivo thrombin generation (TG) guided pilot study AA Barg, T Brutman-Barazani, E Avishai, I Budnik, O Cohen, R Dardik, ... Blood Cells, Molecules, and Diseases 95, 102663, 2022 | 4 | 2022 |
| Bleeding phenotype and hemostatic evaluation by thrombin generation in children with Noonan syndrome: A prospective study AA Barg, Y Yeshayahu, E Avishai, I Budnik, O Cohen, ... Pediatric Blood & Cancer 71 (2), e30761, 2024 | 3 | 2024 |
| Emicizumab prophylaxis in infants: Single‐centre experience S Levy‐Mendelovich, N Greenberg‐kushnir, I Budnik, AA Barg, O Cohen, ... British Journal of Haematology 204 (4), 1375-1382, 2024 | 2 | 2024 |
